Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

PURPOSE: Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin. PATIENTS AND METHODS: This phase I trial asses...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Yap, Timothy A., O’Carrigan, Brent, Penney, Marina S., Lim, Joline S., Brown, Jessica S., de Miguel Luken, Maria J., Tunariu, Nina, Perez-Lopez, Raquel, Rodrigues, Daniel Nava, Riisnaes, Ruth, Figueiredo, Ines, Carreira, Suzanne, Hare, Brian, McDermott, Katherine, Khalique, Saira, Williamson, Chris T., Natrajan, Rachael, Pettitt, Stephen J., Lord, Christopher J., Banerji, Udai, Pollard, John, Lopez, Juanita, de Bono, Johann S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2020
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7499606/
https://ncbi.nlm.nih.gov/pubmed/32568634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02404
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi